Comcast Corporation Message Board
- Reply to
who you kidding shorts? Do the DD. Break Thru Blockbusters. Potential $50+ Stock.
by rondiamond510 •Mar 7, 2013 12:10 PMcouldn't have said it better.
- Reply to
Celldex Therapeutics: Breakthrough Drugs At A Bargain Price : Seeking Alpha
by carlhill975 •Mar 7, 2013 11:07 AMbump
- Reply to
Article Saying CLDX Report Today is A Positive. LINKED
by michaelroman910 •Mar 7, 2013 11:51 AMloaded up guys.
- Reply to
like we haven't seen this 1,000 times. pull back from shorts then goes right back up.
by terridiamond158 •Mar 7, 2013 12:16 PMwill close green today.
-
see Bloomberg article.
- Reply to
Bought . I can live with $51 a share. Glaxo owns 27% Already. Planning Buyout.
by ilike_dollars •Mar 4, 2013 10:52 AMbump
- Reply to
Piper Jaffary " Approval Coming to THRX Thursday- Then Takeover Target" LINK
by sharkman683 •Mar 4, 2013 3:26 PMthaanks
- Reply to
Bloomberg : GSK Will Buy THRX & Be Leader in Respiratory Drugs.
by sharkman683 •Mar 4, 2013 3:31 PMmakes thrx even more vaaluable
- Reply to
Motley Fool Just Out " Glaxo & THRX Hookup Is a No Brainer" LINK
by larrystone13 •Mar 4, 2013 3:39 PMsays like peanut butter and jelly : )
- Reply to
Bloomberg " Analysts Saying Glaxo To Buy THRX. at $51 A Share" Article.
by moneyandstocks •Mar 4, 2013 10:46 AMthank you
-
Bloomberg
Glaxo May Buy Theravance to Gain New Drugs, Piper Analysts Say
By Makiko Kitamura - Mar 4, 2013
GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, may consider acquiring Theravance Inc. (THRX) to fully control respiratory drugs the companies developed together, analysts said.
The Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee will review the two companies’ Breo drug on March 7. Glaxo currently owns 27 percent of Theravance and may pay $51 a share for the remainder, Piper Jaffray analysts said in a note to investors. That’s more than double the closing price on March 1 and would value the remaining stake at about $3.6 billion - Reply to
JAGS REPORT 3/1 AEGIS REINTERATES BUY ON AMRN WITH $35 TARGET. // LINK //
by spencer_doc •Mar 2, 2013 5:55 PMburnt shorts on Mon
-
Skip to content
WebMD: Better information. Better health.
Enter Search Keywords. Use the arrow keys to navigate suggestions.
Treating High Triglycerides
About VASCEPA®
(vas-EE-puh)
The First FDA Approved EPA-only Omega-3
High Triglycerides
Introducing Vascepa (icosapent ethyl)
The First FDA Approved
EPA-only Omega-3
Learn More
High Triglycerides -
thanxs
- Reply to
Benzinga" Aegis Capital Reiterates Buy Rating, $35 PT on FY2012 Financial Results" LINK
by theman111knows •Mar 2, 2013 6:11 PM$$
-
smart
- Reply to
Yahoo Finance Analyst Opinions- Mean Target $18 High Target $35 //////////// POSTED
by stevemason320 •Mar 2, 2013 1:06 PMthanxs